The operational strategy for amyotrophic lateral sclerosis (ALS) clinical trials is markedly more complex than those for traditional pharmaceuticals. Biorasi has the in-depth knowledge and experience in ALS pathobiology and treatment to design that you need.
Removing the obstacles to patient engagement
Biorasi is your expert advisor in the ALS study ecosystem. Our experience includes:
- Working with patient advocacy groups to remove obstacles to engagement for ALS subjects.
- Deploying a global strategy, including an international recruitment campaign, designed to reach potential patients.
- Optimizing decentralized strategies such as remote treatment and medical device clinical trial monitoring.
What Went Wrong: Three Major Challenges to Alzheimer’s Disease Drug Discovery
Biorasi Completes Rare Nephrology Trial During COVID-19
WSCS 2020 Wrap Up: Biorasi joins the global dialogue for regenerative medicine